Predict your next investment

Corporation
CONSUMER PRODUCTS & SERVICES
cancerresearchuk.org

See what CB Insights has to offer

Investments

5

Portfolio Exits

2

Funds

1

Partners & Customers

10

About Cancer Research UK

Cancer Research UK is an independent charity dedicated to cancer research.

Cancer Research UK Headquarter Location

407 St John Street

London, England, EC1V 4AD,

United Kingdom

+44 20 3469 6400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cancer Research UK Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cancer Research UK Rank

Latest Cancer Research UK News

Carnival time in Buckingham in aid of Cancer Research UK

Jun 23, 2022

It’s carnival time in Buckingham on Saturday, June 25, when the Cancer Research UK Carnival comes to Embleton Way. By Hannah Richardson Thursday, 23rd June 2022, 11:52 am The day will start with a parade and end with a parade – but they will be very different in tone and content. Few of us have avoided being affected in some way by cancer, either directly or through friends or family members, and Saturday’s fundraising event is a chance to have fun at the same time as contributing to Cancer UK’s invaluable research into the disease. The fun will start with a colourful opening parade, whilst the Lanterns of Light parade at the end of the day will be a time to reflect and remember loved ones lost to cancer. Sign up to our daily newsletter Sign up Submitting... This site is protected by reCAPTCHA and the Google Privacy Notice and Terms of Service apply. Volunteers Cath Stroud and Linda Woodham sell Candle of Hope bags at the 2018 Cancer Research UK Relay for Life in Buckingham The carnival will be opened at 10.30am by well-known local figure Ken Parker and his guide dog, Henry, after which the first lap undertaken by everyone who can be there to make it a celebration and fitting way to start the fun of the day. The Ferris wheel will provide unique views over Buckingham , and there will be inflatables for all ages of children, plus a variety of food outlets, games, traditional stalls and sideshows including a tombola. Children’s team relays will take place in the arena from noon to 2.30pm. Relays will be in teams of four children in different age groups and children need to be registered for the various heats before noon on the day. As well as the activities around the arena, a programme of music will be on offer, starting with the Adele Peters’ Singers and Dancers at 2.30pm. Following on at 4pm will be The Winslow Concert Band, 5pm The Buckingham Ukulele Group and 6.15pm The Dhol Show. The 60’s Jukebox band will end the day’s fun and enjoyment with a range of classics from the 1960s. This will be followed by a change of mood, with the Lanterns of Light Parade taking place after a brief ceremony of music and words at 10.15pm. Those familiar with Buckingham’s previous Relay for Life events, held over 14 years at Bourton Meadow Academy in aid of Cancer Research UK , will remember the similar Candle of Hope ceremony. Lanterns will be available at the carnival to dedicate to loved ones lost or those still battling bravely.

Cancer Research UK Investments

5 Investments

Cancer Research UK has made 5 investments. Their latest investment was in BioCaptiva as part of their Seed VC on June 6, 2022.

CBI Logo

Cancer Research UK Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/2/2022

Seed VC

BioCaptiva

$2.64M

Yes

2

9/6/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

1/4/2019

Grant

Subscribe to see more

Subscribe to see more

10

1/4/2019

Grant

Subscribe to see more

Subscribe to see more

10

10/5/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/2/2022

9/6/2021

1/4/2019

1/4/2019

10/5/2016

Round

Seed VC

Seed VC

Grant

Grant

Series A

Company

BioCaptiva

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.64M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

Cancer Research UK Portfolio Exits

2 Portfolio Exits

Cancer Research UK has 2 portfolio exits. Their latest portfolio exit was Monte Rosa Therapeutics on June 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/24/2021

IPO

$99M

17

3/31/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/24/2021

3/31/2021

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

17

10

Cancer Research UK Fund History

1 Fund History

Cancer Research UK has 1 fund, including SV7 Health Impact Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/2/2019

SV7 Health Impact Fund

$252M

1

Closing Date

7/2/2019

Fund

SV7 Health Impact Fund

Fund Type

Status

Amount

$252M

Sources

1

Cancer Research UK Partners & Customers

10 Partners and customers

Cancer Research UK has 10 strategic partners and customers. Cancer Research UK recently partnered with Lineage Cell Therapeutics on April 4, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

4/13/2022

Partner

United States

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

Lineage Cell Therapeutics , Inc. 's clinical programs are in markets with billion dollar opportunities and include four allogeneic product candidates : OpRegen , a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration , which is now being developed under a worldwide collaboration with Roche and Genentech , a member of the Roche ; OPC1 , an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries ; VAC2 , a dendritic cell therapy produced from Lineage Cell Therapeutics , Inc. 's VAC technology platform for immuno-oncology and infectious disease , currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and ANP1 , an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy .

4

2/3/2022

Partner

United Kingdom

Wigan Warriors reveal charity third kit featuring Cancer Research UK for the 2022 season

Rachael Hodgkinson , from Cancer Research UK , said : `` We are really excited about working in partnership with Wigan Warriors .

1

6/23/2021

Partner

United States

Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

Under the terms of the clinical development partnership , Cancer Research UK 's Centre for Drug Development will fund , sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001 , which will be led by Dr Amit Patel 's Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester , UK .

2

6/23/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

3/3/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/13/2022

2/3/2022

6/23/2021

6/23/2021

3/3/2021

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United Kingdom

United States

United States

United States

News Snippet

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

Lineage Cell Therapeutics , Inc. 's clinical programs are in markets with billion dollar opportunities and include four allogeneic product candidates : OpRegen , a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration , which is now being developed under a worldwide collaboration with Roche and Genentech , a member of the Roche ; OPC1 , an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries ; VAC2 , a dendritic cell therapy produced from Lineage Cell Therapeutics , Inc. 's VAC technology platform for immuno-oncology and infectious disease , currently in Phase 1 clinical development for the treatment of non-small cell lung cancer and ANP1 , an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy .

Wigan Warriors reveal charity third kit featuring Cancer Research UK for the 2022 season

Rachael Hodgkinson , from Cancer Research UK , said : `` We are really excited about working in partnership with Wigan Warriors .

Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

Under the terms of the clinical development partnership , Cancer Research UK 's Centre for Drug Development will fund , sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001 , which will be led by Dr Amit Patel 's Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester , UK .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Cancer Research UK Team

2 Team Members

Cancer Research UK has 2 team members, including former Chief Financial Officer, Rita Akushie.

Name

Work History

Title

Status

Mel Nurse

Founder

Current

Rita Akushie

Chief Financial Officer

Former

Name

Mel Nurse

Rita Akushie

Work History

Title

Founder

Chief Financial Officer

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.